12 Oct Scheer Partners Represents Immunomic Therapeutics in New Lease for Rockville Lab Space
Rockville, MD – A Pennsylvania-based biotechnology company has opened an R&D facility in Rockville, the result of a transaction completed by two Scheer Partners executives.
The leading provider of fully integrated commercial real estate services for the health science industry in the Washington and Baltimore metropolitan areas, Scheer Partners announces today that it has negotiated on behalf of Immunomic Therapeutics in a 3,500-square-foot lease of laboratory space at 15010 Broschart Road, which is owned by Pasadena, Calif.-based Alexandria Real Estate Equities.
In this new multi-year lease, Scheer Partners Senior Vice President Henry Bernstein and Vice President Matt Brady represented Immunomic Therapeutics, a clinical-stage biotech company headquartered in Lancaster, Pa.
Previously, Immunomic Therapeutics occupied a small amount of temporary lab space in Montgomery County before recently settling into its new Rockville facility on Broschart Road.
The privately held company is developing next-generation vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) technology, which emerged from $20 million of National Institutes of Health-funded research conducted by Dr. Tom August at the Johns Hopkins University School of Medicine.
Immunomic Therapeutics has the exclusive worldwide license to the LAMP technology patent estate and is working to commercialize ground-breaking vaccines, with an initial concentration in allergy, cancer and infectious diseases.
The company’s vaccine platform significantly increases the effectiveness of the immune system’s response to nucleic-acid vaccines, while simplifying overall vaccine design and delivery. This, in turn, yields safer, more cost-efffective human and animal therapies.
Says Bernstein: “We’re extremely pleased to have secured new R&D space in Rockville for Immunomic Therapeutics. Led by long-time biotech entrepreneur Bill Hearl, the company’s founder and CEO, Immunomic Therapeutics is an extremely promising biotech firm focused on becoming the leading commercial DNA vaccine company.”